Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Uveal Melanoma 1Serotonin Syndrome 1Rectal Neoplasms 1Malignant Carcinoid Syndrome 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

telotristat ethyl 5lanreotide 2telotristat 1pasireotide 1lutetium Lu 177 dotatate 1alpha-methyltryptophan 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Random Allocation 1Panitumumab 1Octreotide 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Serotonin Syndrome × Receptor-Like Protein Tyrosine Phosphatases, Class 2 × Clear all
NCT00092287 2020-04-30

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Ipsen

Phase 3 Terminated
4 enrolled
Endocrine

Malignant Carcinoid Syndrome, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡